New investigational drugs for androgenetic alopecia

Isabel Cristina Valente Duarte De Sousa, Antonella Tosti

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: Androgenetic alopecia (AGA) is the most common form of hair loss, however current treatment options are limited and moderately effective. In the past few years, there has been an increased interest in deciphering the molecular mechanisms responsible for this disorder, which has opened the possibility of novel treatments that promise to not only stimulate hair growth, but also to induce formation of new hair follicles. Areas covered: The future holds more effective topical treatments with less systemic side effects (such as topical 5-alfa-reductase inhibitors), prostaglandin analogs and antagonists, medications which act through the Wnt signaling pathway, stem cells for hair regeneration, platelet-rich plasma (PRP) and more effective ways of transplanting hair. A comprehensive search was made using PubMed, GoogleScholar and Clinicaltrial.gov using different combination of key words, which included AGA treatment, new treatments for AGA, Wnt pathway, prostaglandins, PRP and stem cells for hair regrowth. Expert opinion: In the near future, treatments with topical 5-alfa-reductase inhibitors and prostaglandin agonists or antagonists are expected. More evidence is needed to verify the efficacy of PRP. Although hair follicle bioengineering and multiplication is a fascinating and promising field, it is still a long way from being available to clinicians.

Original languageEnglish
Pages (from-to)573-589
Number of pages17
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Investigational Drugs
Alopecia
Hair
Platelet-Rich Plasma
5-alpha Reductase Inhibitors
Wnt Signaling Pathway
Hair Follicle
Prostaglandins
Stem Cells
Synthetic Prostaglandins
Prostaglandin Antagonists
Bioengineering
Expert Testimony
Plasma Cells
PubMed
Regeneration
Growth

Keywords

  • 5-alfa-reductase inhibitors
  • Androgenetic alopecia
  • Dutasteride
  • Finasteride
  • Hair stimulating complex
  • Minoxidil
  • Platelet rich plasma
  • Prostaglandins
  • Stem cells
  • Wnt signaling

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New investigational drugs for androgenetic alopecia. / Valente Duarte De Sousa, Isabel Cristina; Tosti, Antonella.

In: Expert Opinion on Investigational Drugs, Vol. 22, No. 5, 01.05.2013, p. 573-589.

Research output: Contribution to journalArticle

Valente Duarte De Sousa, Isabel Cristina ; Tosti, Antonella. / New investigational drugs for androgenetic alopecia. In: Expert Opinion on Investigational Drugs. 2013 ; Vol. 22, No. 5. pp. 573-589.
@article{e104a518466945c6b3219492e5df43ed,
title = "New investigational drugs for androgenetic alopecia",
abstract = "Introduction: Androgenetic alopecia (AGA) is the most common form of hair loss, however current treatment options are limited and moderately effective. In the past few years, there has been an increased interest in deciphering the molecular mechanisms responsible for this disorder, which has opened the possibility of novel treatments that promise to not only stimulate hair growth, but also to induce formation of new hair follicles. Areas covered: The future holds more effective topical treatments with less systemic side effects (such as topical 5-alfa-reductase inhibitors), prostaglandin analogs and antagonists, medications which act through the Wnt signaling pathway, stem cells for hair regeneration, platelet-rich plasma (PRP) and more effective ways of transplanting hair. A comprehensive search was made using PubMed, GoogleScholar and Clinicaltrial.gov using different combination of key words, which included AGA treatment, new treatments for AGA, Wnt pathway, prostaglandins, PRP and stem cells for hair regrowth. Expert opinion: In the near future, treatments with topical 5-alfa-reductase inhibitors and prostaglandin agonists or antagonists are expected. More evidence is needed to verify the efficacy of PRP. Although hair follicle bioengineering and multiplication is a fascinating and promising field, it is still a long way from being available to clinicians.",
keywords = "5-alfa-reductase inhibitors, Androgenetic alopecia, Dutasteride, Finasteride, Hair stimulating complex, Minoxidil, Platelet rich plasma, Prostaglandins, Stem cells, Wnt signaling",
author = "{Valente Duarte De Sousa}, {Isabel Cristina} and Antonella Tosti",
year = "2013",
month = "5",
day = "1",
doi = "10.1517/13543784.2013.784743",
language = "English",
volume = "22",
pages = "573--589",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - New investigational drugs for androgenetic alopecia

AU - Valente Duarte De Sousa, Isabel Cristina

AU - Tosti, Antonella

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Introduction: Androgenetic alopecia (AGA) is the most common form of hair loss, however current treatment options are limited and moderately effective. In the past few years, there has been an increased interest in deciphering the molecular mechanisms responsible for this disorder, which has opened the possibility of novel treatments that promise to not only stimulate hair growth, but also to induce formation of new hair follicles. Areas covered: The future holds more effective topical treatments with less systemic side effects (such as topical 5-alfa-reductase inhibitors), prostaglandin analogs and antagonists, medications which act through the Wnt signaling pathway, stem cells for hair regeneration, platelet-rich plasma (PRP) and more effective ways of transplanting hair. A comprehensive search was made using PubMed, GoogleScholar and Clinicaltrial.gov using different combination of key words, which included AGA treatment, new treatments for AGA, Wnt pathway, prostaglandins, PRP and stem cells for hair regrowth. Expert opinion: In the near future, treatments with topical 5-alfa-reductase inhibitors and prostaglandin agonists or antagonists are expected. More evidence is needed to verify the efficacy of PRP. Although hair follicle bioengineering and multiplication is a fascinating and promising field, it is still a long way from being available to clinicians.

AB - Introduction: Androgenetic alopecia (AGA) is the most common form of hair loss, however current treatment options are limited and moderately effective. In the past few years, there has been an increased interest in deciphering the molecular mechanisms responsible for this disorder, which has opened the possibility of novel treatments that promise to not only stimulate hair growth, but also to induce formation of new hair follicles. Areas covered: The future holds more effective topical treatments with less systemic side effects (such as topical 5-alfa-reductase inhibitors), prostaglandin analogs and antagonists, medications which act through the Wnt signaling pathway, stem cells for hair regeneration, platelet-rich plasma (PRP) and more effective ways of transplanting hair. A comprehensive search was made using PubMed, GoogleScholar and Clinicaltrial.gov using different combination of key words, which included AGA treatment, new treatments for AGA, Wnt pathway, prostaglandins, PRP and stem cells for hair regrowth. Expert opinion: In the near future, treatments with topical 5-alfa-reductase inhibitors and prostaglandin agonists or antagonists are expected. More evidence is needed to verify the efficacy of PRP. Although hair follicle bioengineering and multiplication is a fascinating and promising field, it is still a long way from being available to clinicians.

KW - 5-alfa-reductase inhibitors

KW - Androgenetic alopecia

KW - Dutasteride

KW - Finasteride

KW - Hair stimulating complex

KW - Minoxidil

KW - Platelet rich plasma

KW - Prostaglandins

KW - Stem cells

KW - Wnt signaling

UR - http://www.scopus.com/inward/record.url?scp=84876211904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876211904&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.784743

DO - 10.1517/13543784.2013.784743

M3 - Article

VL - 22

SP - 573

EP - 589

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -